Patient characteristics
| . | No. (%) or median (IQR) . |
|---|---|
| Patient demographics at enrollment (52 patients) | |
| Median age, y (range) | 42 (23-69) |
| Sex, % male | 88 |
| Ethnicity, % white/black/other | 58/35/8 |
| Serum CRP, mg/L | 75 (7-136) |
| Plasma HHV8, copies/mL | 30 000 (60.5-1 000 000) |
| Active MCD, % | 81 |
| MCD-related information during follow-up (610 sample points) | |
| Median serum CRP, mg/L | 6 (0-24) |
| Median plasma HHV8 viral load, copies/mL | 890 (0-2400) |
| Median CRP during attack | 38.5 (8-110.75) |
| Median CRP during remission | 3 (0-9) |
| Median plasma HHV8 viral load during attack | 27 000 (2700-400 000) |
| Median plasma HHV8 viral load during remission | 0 (0-1950) |
| Percent follow-up with CRP > 10 mg/L during attack | 73.4 |
| Percent with CRP > 10 mg/L during remission | 19.6 |
| Percent with detectable plasma HHV8 during attack | 90.5 |
| Percent with detectable plasma HHV8 during remission | 38.6 |
| . | No. (%) or median (IQR) . |
|---|---|
| Patient demographics at enrollment (52 patients) | |
| Median age, y (range) | 42 (23-69) |
| Sex, % male | 88 |
| Ethnicity, % white/black/other | 58/35/8 |
| Serum CRP, mg/L | 75 (7-136) |
| Plasma HHV8, copies/mL | 30 000 (60.5-1 000 000) |
| Active MCD, % | 81 |
| MCD-related information during follow-up (610 sample points) | |
| Median serum CRP, mg/L | 6 (0-24) |
| Median plasma HHV8 viral load, copies/mL | 890 (0-2400) |
| Median CRP during attack | 38.5 (8-110.75) |
| Median CRP during remission | 3 (0-9) |
| Median plasma HHV8 viral load during attack | 27 000 (2700-400 000) |
| Median plasma HHV8 viral load during remission | 0 (0-1950) |
| Percent follow-up with CRP > 10 mg/L during attack | 73.4 |
| Percent with CRP > 10 mg/L during remission | 19.6 |
| Percent with detectable plasma HHV8 during attack | 90.5 |
| Percent with detectable plasma HHV8 during remission | 38.6 |
IQR indicates interquartile range; CRP, C-reactive protein; HHV8, human herpesvirus-8; and MCD, multicentric Castleman disease.